Erenumab following treatment discontinuation

Francesca Schiano Di Cola,Salvatore Caratozzolo,Matteo Cortinovis,Paolo Liberini,Renata Rao,Alessandro Padovani

JOURNAL OF THE NEUROLOGICAL SCIENCES（2021）

引用 0|浏览1

暂无评分

摘要

Current national regulations request a three months discontinuation following a 12 months treatment cycle with monoclonal antibodies targeting CGRP. Aim of the present study was to assess migraine outcome following erenumab discontinuation and subsequent re-treatment.

查看译文

关键词

treatment,discontinuation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要